Table 2.
| TIM-3 | Number of positive cells per HPF | VISTA | Number of positive cells per HPF | |||||
|---|---|---|---|---|---|---|---|---|
| Positive cases | Number of cases | Positive cases | Number of cases | |||||
| n (%) | 5–10 (1+) | 10–20 (2+) | >20 (3+) | n (%) | 5–10 (1+) | 10–20 (2+) | >20 (3+) | |
| PTCL, NOS | 2/37 (5) | 0 | 0 | 2 | 1/37 (2) | 1 | 0 | 0 |
| ALCL | 2/11 (18) | 2 | 0 | 0 | 0/11 (0) | 0 | 0 | 0 |
| AITL | 0/6 (0) | 0 | 0 | 0 | 0/6 (0) | 0 | 0 | 0 |
| EATL | 0/3 (0) | 0 | 0 | 0 | 0/3 (0) | 0 | 0 | 0 |
| ENKTCL | 0/3 (0) | 0 | 0 | 0 | 0/3 (0) | 0 | 0 | 0 |
AITL, angioimmunoblastic T cell lymphoma; ALCL, anaplastic large cell lymphoma; EATL, enteropathy-associated T cell lymphoma; ENKTCL, extranodal natural killer T cell lymphoma; HPF, high power field; PTCL, peripheral T cell lymphoma; TIM-3, T cell immunoglobulin-3; VISTA, V-domain Ig-containing suppressor of T cell activation.